文献速递前列腺癌

镭-223联合阿比特龙/泼尼松或恩扎卢胺治疗mCRPC的真实世界结局

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-05-13

本研究利用Flatiron Health数据库回顾性分析625例接受镭-223治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,22%联用阿比特龙/泼尼松、27%联用恩扎卢胺,多采用序贯而非同期给药;中位随访9个月,症状性骨骼事件发生率为0.35例/人年,病理骨折为0.11例/人年,mCRPC诊断后中位总生存28.1个月;使用骨健康药物时症状性骨骼事件发生率降低,但骨健康药物使用不足。

要点

  • 真实世界中镭-223常与阿比特龙/泼尼松或恩扎卢胺联用,多采用序贯方式。
  • 症状性骨骼事件发生率为0.35例/人年,病理骨折为0.11例/人年。
  • 骨健康药物可降低症状性骨骼事件发生率,但临床使用不足。

核心结论

  • 真实世界中镭-223联合阿比特龙/泼尼松或恩扎卢胺治疗常见,且多采用序贯而非同期给药。
  • 使用骨健康药物时症状性骨骼事件发生率降低,但骨健康药物使用不足。

研究设计与样本

  • 基于Flatiron Health数据库的回顾性研究,纳入625例接受镭-223治疗的mCRPC患者。
  • 同期给药定义为两药起始间隔在30天内,序贯给药定义为第二种药物在第一种开始后≥30天启动。
  • 索引日期为首次镭-223剂量日,中位随访9个月。

主要发现

  • 625例接受镭-223治疗的患者中,22%联用阿比特龙/泼尼松,27%联用恩扎卢胺。
  • 联合治疗中73%为序贯给药,23%为同期给药。
  • 67%的患者曾接受骨健康药物,55%的患者同时接受骨健康药物。
  • 症状性骨骼事件发生率为0.35例/人年,病理骨折发生率为0.11例/人年。
  • mCRPC诊断后中位总生存为28.1个月。

关键数值与推荐

  • 同期给药:两种药物起始间隔在30天内;序贯给药:第二种药物在第一种开始后≥30天启动。
  • 症状性骨骼事件发生率为0.35例/人年,病理骨折发生率为0.11例/人年。
  • mCRPC诊断后中位总生存为28.1个月。

临床怎么用

  • 真实世界中镭-223可与阿比特龙/泼尼松或恩扎卢胺联合使用,但多采用序贯方式。
  • 应重视骨健康药物的使用,以降低症状性骨骼事件风险。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 中位随访时间较短(9个月),可能影响长期结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: We used the Flatiron Health database to perform a retrospective study of patients with mCRPC treated with radium-223. Treatment with radium-223 plus abiraterone/prednisone or enzalutamide was defined as concurrent if both drugs started within 30 days of one another, or layered when the second drug started ≥30 days after the first. The index date was defined as the day of the first radium-223 dose. Outcome measures included symptomatic skeletal events (SSEs), overall survival (OS), and patterns of treatments received. RESULTS: Of the 625 patients treated with radium-223, 22% received it together with abiraterone/prednisone and 27% with enzalutamide. When these agents were combined, they were often initiated in a layered fashion (73% layered, 23% concurrent). Prior or concomitant bone health agents (BHAs) were received by 67% and 55% of patients, respectively. Median follow-up was 9 months. Overall, incidence rates for SSEs and pathologic fractures were 0.35 and 0.11 patients per person-year, respectively. Median OS from mCRPC diagnosis was 28.1 months. CONCLUSIONS: In this real-world setting, combination treatments with radium-223 and abiraterone/prednisone or enzalutamide were common. These agents were more commonly given in a layered than a concurrent fashion. Incidence rates for SSEs were reduced when BHAs were used; however, BHAs were underutilized.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore N, Higano CS, George DJ, et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32404868. doi:10.1038/s41391-020-0236-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。